Snack info board

[StockDetective]

$ARYC Silicon Valley biotech stock Arrayit Corporation.

Due Diligence link:

https://cdn.discordapp.com/attachments/357369664193560596/459932549062590475/Arrayit_Due_Diligence_Report_.pdf


Arrayit Corporation Reports Clinical Instrumentation Sale to the FDA

Sunnyvale, July 16, 2018 (GLOBE NEWSWIRE) -- July 16, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH). The instrumentation reads and reports test results for the company’s allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson’s Disease (PD).

Arrayit recently scored 100% on immunoglobulin E (IgE) proficiency testing with the College of American Pathologists, announced a nationwide sales network of 1,700 professional sales representatives to sell and distribute the company’s finger stick tests, and completed pilot testing with one the nation’s largest chains of retail stores. Arrayit microarray tests conveniently use a few drops of blood collected on a blood card to assist doctors in identifying and treating allergy, asthma, dietary intolerance and pipeline indications for ovarian cancer and PD. The company recently met with top officials at the FDA to discuss FDA approval of a major product line. The FDA ensures the safety of food, drugs and medical devices by regulating consumer products exceeding $1,000,000,000,000 ($1 trillion) in annual revenues.

Arrayit CEO Rene Schena states, “The sale of clinical instrumentation to the FDA advances our personalized medicine initiatives by strengthening ties with the nation’s preeminent regulatory agency. Our transformative healthcare products and services benefit from transparency in the hands of top FDA scientists.”

https://www.nasdaq.com/press-release/arrayit-corporation-reports-clinical-instrumentation-sale-to-the-united-states-food-and-drug-20180716-00167


August 13, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens. Two thousand retail locations nationwide averaging 3,000 customer visits per store per day would give Arrayit access to 6 million retail customers daily, creating the potential for exponential sales growth. This promotional campaign required rigorous vetting and high-level corporate approval by the retailer, which reports revenues exceeding $50 billion annually.

Arrayit recently completed an allergy testing pilot program for a retail chain, established a nationwide network of 1,700 sales professionals to sell and distribute the company’s finger stick microarray tests, met with top officials at the United States Food and Drug Administration (FDA) regarding FDA approval of a major product line, reported the sale of clinical instrumentation to the FDA, and signed allergy testing contracts with a consortium of 178 medical clinics. Doctors can use allergy test results as a guide to prescribe allergy medicines, immunotherapy, food elimination and lifestyle changes. The availability of allergy medicines and immunotherapy products at retail stores, allows customers to incorporate an allergy test into a convenient family shopping experience.

https://www.yahoo.com/amphtml/finance/news/arrayit-corporation-receives-approval-store-093000820.html

August 27, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces allergy testing partnerships with multiple providers of allergen immunotherapy products including sub-cutaneous, sublingual, and oral allergy medicines designed to treat patients of allergy and asthma. Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe, effective and convenient allergy medicines for their allergy and asthma patients, including custom immunotherapy products formulated upon review of quantitative allergy test results.

Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding FDA approval of a major product line, reported the sale of clinical instrumentation to the FDA, signed allergy testing contracts with a consortium of 178 medical clinics and received approval for in-store promotions by a major retailer. Arrayit’s new therapeutics partners provide a seamless solution to doctors who diagnose and treat the more than 50 million Americans reporting allergic symptoms annually.


https://www.yahoo.com/amphtml/finance/news/arrayit-corporation-announces-allergy-testing-093000949.html